Walgreens (NYSE: WAG) (Nasdaq: WAG) had October sales of $6.37 billion,
an increase of 6.1 percent from $6.0 billion for the same month in
fiscal 2013.
Total front-end sales increased 3.5 percent compared with the same month
in fiscal 2013, while comparable store front-end sales increased 2.3
percent. Customer traffic in comparable stores increased 0.6 percent
while basket size increased 1.7 percent.
Prescriptions filled at comparable stores increased by 5.7 percent in
October and increased 6.2 percent on a calendar day-shift adjusted
basis. This year’s October had one additional Thursday and one fewer
Monday compared with October 2012. These calendar shifts negatively
impacted prescriptions filled at comparable stores by 0.5 percentage
point.
Prescriptions filled at comparable stores also were positively impacted
by 1.1 percentage points due to more flu shots versus last year and were
negatively impacted by 0.2 percentage point due to lower incidence of
flu in this year’s October.
October pharmacy sales increased by 7.8 percent, while comparable store
pharmacy sales increased 7.9 percent and increased by a calendar
day-shift adjusted 8.4 percent. Calendar day shifts negatively impacted
pharmacy sales in comparable stores by 0.5 percentage point. Calendar
day-shift adjusted comparable store pharmacy sales were negatively
impacted by 1.0 percentage point due to generic drug introductions in
the last 12 months, and were positively impacted by 0.7 percentage point
due to more flu shots versus last year. Pharmacy sales accounted for
65.5 percent of total sales for the month.
Flu shots administered at pharmacies and clinics season to date were
more than 4.9 million versus nearly 3.6 million last year.
Sales in comparable stores increased by 5.8 percent in October. Calendar
day shifts negatively impacted total comparable sales by 0.3 percentage
point, while generic drug introductions in the last 12 months negatively
impacted total comparable sales by 0.7 percentage point.
Calendar 2013 sales to date were $60.47 billion, an increase of 4.3
percent from $57.97 billion in 2012.
Fiscal 2014 year-to-date sales for the first two months were $12.29
billion, up 7.0 percent from $11.49 billion in the comparable period in
fiscal 2013.
Walgreens opened 14 stores during October, including four relocations,
and closed two.
|
|
October Comparable Sales and Prescriptions Filled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actual
|
|
|
Calendar Shift Impact
|
|
|
Generics Impact
|
|
|
Cough, Cold, Flu Impact
|
|
|
Flu Shot Impact
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comp Sales
|
|
5.8%
|
|
|
- 0.3%
|
|
|
- 0.7%
|
|
|
- 0.1%
|
|
|
0.5%
|
|
Comp Front End
|
|
2.3%
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Comp Rx Sales
|
|
7.9%
|
|
|
- 0.5%
|
|
|
- 1.0%
|
|
|
- 0.1%
|
|
|
0.7%
|
|
Comp Rx Scripts
|
|
5.7%*
|
|
|
- 0.5%
|
|
|
-
|
|
|
- 0.2%
|
|
|
1.1%
|
|
* Includes +1.9 percentage points from patients filling more 90-day
prescriptions
On Oct. 31, Walgreens operated 8,597 locations in all 50 states, the
District of Columbia, Puerto Rico, Guam and the U.S. Virgin Islands.
That includes 8,131 drugstores, 101 more than a year ago, including five
net stores acquired over the last 12 months. The company also operates
infusion and respiratory services facilities, specialty pharmacies and
mail service facilities. Its Take Care Health Systems subsidiary manages
more than 750 in-store convenient care clinics and worksite health and
wellness centers.
Please note: Sales numbers and the adjustments shown in the table are
preliminary, unaudited and subject to revision. Comparable stores are
defined as those drugstore locations open for at least 12 consecutive
months without closure for seven or more consecutive days and without a
major remodel or a natural disaster in the past 12 months. Acquired
operating locations and relocations are not included as comparable
stores for the first 12 months after the acquisition or relocation.
Cautionary Note Regarding Forward-Looking Statements: Statements
in this release that are not historical are forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words such as "expect," “likely,”
"outlook," “forecast,” "would," "could," "should," “can,” “will,”
"project," "intend," "plan," "goal,” “target,” “continue," "sustain,"
“synergy,” "on track," "believe," "seek," "estimate," "anticipate,"
"may," “possible,” "assume," and variations of such words and similar
expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future
performance and involve risks, assumptions and uncertainties, including,
but not limited to, those described in Item 1A (Risk Factors) of our
most recent Annual Report on Form 10-K which is incorporated herein by
reference, and in other documents that we file or furnish with the
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those indicated or
anticipated by such forward-looking statements. Accordingly, you are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date they are made. Except to the
extent required by law, Walgreens does not undertake, and expressly
disclaims, any duty or obligation to update publicly any forward-looking
statement after the date of this release, whether as a result of new
information, future events, changes in assumptions or otherwise.
Copyright Business Wire 2013